Manisha Girotra is Chief Executive Officer of Moelis & Company in India. She was previously Chairperson and Country Head for UBS in India, with a career spanning 16 years with UBS in Hong Kong, Mumbai, Delhi and London. Prior to UBS, Manisha ran Barclays de Zoete Wedd’s investment bank activities in Delhi.
At UBS, Manisha oversaw the multiple businesses of the firm in India, including investment banking, equities trading, a propriety equity/equity linked investment book of US$ 1bn, wealth management and a US$ 1bn onshore lending book.
Manisha has led successful executions of several landmark transactions including the US$ 5bn merger of Grasim and Ultratech’s cement business, Genpact’s US$ 550mn acquisition of Headstrong, Tech Mahindra’s US$650mn acquisition of Satyam Computers, Reliance Industries’ joint venture with Pioneer Natural Resouces and Newpek, Reliance Power’s US$ 2.6bn IPO, Zain’s US$ 10.7bn sale to Bharti Airtel, Vodafone’s US$ 13bn acquisition of HTIL’s interest in Hutch Essar, Warburg Pincus US$ 500mn divestiture of stake in Bharti Airtel, Unitech’s US$ 1.2bn sale of 67.25% stake in its telecom business to Telenor, US$ 600mn sale of Spice Telecom to Idea, Birla Group’s US$ 6b acquisition of Novelis, Essar Steel’s US$ 1.6bn acquisition of Algoma Steel, UB Group’s US$ 1.2bn acquisition of Whyte and Mackay amongst others.
At Moelis, she has led the execution of £3.5bn investment by Vedanta Group in Anglo American, US$ 1.9bn sale of Strides injectables division (Agila) to Mylan Inc, US$ 800mn sale of Bharti’s African towers to Eaton and Capital International, US$ 2.5bn acquisition of Aleris by Novelis‐Hindalco, £ 603mn acquisition of UK & Ireland Generic Business of Teva by Intas Pharma, US$ 500mn restructuring of Essar’s US coal assets, US$ 300mn investment in GMR Energy by Tenaga Nasional, US$ 255mn sale of Advent’s stake in Care Hospitals to Abraaj, US$ 350mn minority acquisition by ChrysCap of Mankind Pharma.